GB0021487D0 - Pharmaceutical - Google Patents

Pharmaceutical

Info

Publication number
GB0021487D0
GB0021487D0 GBGB0021487.4A GB0021487A GB0021487D0 GB 0021487 D0 GB0021487 D0 GB 0021487D0 GB 0021487 A GB0021487 A GB 0021487A GB 0021487 D0 GB0021487 D0 GB 0021487D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0021487.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Priority to GBGB0021487.4A priority Critical patent/GB0021487D0/en
Publication of GB0021487D0 publication Critical patent/GB0021487D0/en
Priority to PCT/IB2001/001525 priority patent/WO2002017963A2/en
Priority to US09/939,093 priority patent/US20040185094A1/en
Priority to CA002420852A priority patent/CA2420852A1/en
Priority to AU2001282377A priority patent/AU2001282377A1/en
Priority to EP01960993A priority patent/EP1313507A2/en
Priority to JP2002522936A priority patent/JP2004517046A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
GBGB0021487.4A 2000-09-01 2000-09-01 Pharmaceutical Ceased GB0021487D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB0021487.4A GB0021487D0 (en) 2000-09-01 2000-09-01 Pharmaceutical
PCT/IB2001/001525 WO2002017963A2 (en) 2000-09-01 2001-08-24 Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction
US09/939,093 US20040185094A1 (en) 2000-09-01 2001-08-24 Pharmaceutical
CA002420852A CA2420852A1 (en) 2000-09-01 2001-08-24 Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction
AU2001282377A AU2001282377A1 (en) 2000-09-01 2001-08-24 Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction
EP01960993A EP1313507A2 (en) 2000-09-01 2001-08-24 Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction
JP2002522936A JP2004517046A (ja) 2000-09-01 2001-08-24 医薬

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0021487.4A GB0021487D0 (en) 2000-09-01 2000-09-01 Pharmaceutical

Publications (1)

Publication Number Publication Date
GB0021487D0 true GB0021487D0 (en) 2000-10-18

Family

ID=9898666

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0021487.4A Ceased GB0021487D0 (en) 2000-09-01 2000-09-01 Pharmaceutical

Country Status (6)

Country Link
EP (1) EP1313507A2 (zh)
JP (1) JP2004517046A (zh)
AU (1) AU2001282377A1 (zh)
CA (1) CA2420852A1 (zh)
GB (1) GB0021487D0 (zh)
WO (1) WO2002017963A2 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
NO20031157L (no) * 2002-03-18 2003-09-19 Jenapharm Gmbh Fremgangsmåte for å identifisere en farmasöytisk aktiv forbindelse for behandling av en tilstand forårsaket av forandret ekspresjon avinsulinreseptoren
ES2222831B2 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8348498A (en) * 1997-07-15 1999-02-10 Zeneca Limited Methods
CN1177831C (zh) * 1998-12-04 2004-12-01 神经研究公司 作为离子通道调节剂的新的苯并咪唑啉酮一、苯并噁唑酮一或苯并噻唑啉酮衍生物
US6803375B1 (en) * 2000-01-06 2004-10-12 The Regents Of The University Of California Non-peptide inhibition of T-lymphocyte activation and therapies related thereto
WO2001054680A2 (en) * 2000-01-26 2001-08-02 Cedars-Sinai Medical Center Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor

Also Published As

Publication number Publication date
JP2004517046A (ja) 2004-06-10
EP1313507A2 (en) 2003-05-28
WO2002017963A2 (en) 2002-03-07
CA2420852A1 (en) 2002-03-07
AU2001282377A1 (en) 2002-03-13
WO2002017963A3 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
GB0006133D0 (en) Novel pharmaceutical
GB0025473D0 (en) Pharmaceutical combinations
GB0020691D0 (en) Pharmaceutical combination
GB0031084D0 (en) Pharmaceutical compounds
GB0012291D0 (en) Pharmaceutical combination
GB0021865D0 (en) Novel pharmaceutical
GB0019228D0 (en) Novel pharmaceutical
GB0019272D0 (en) Pharmaceutical compounds
GB0014006D0 (en) Novel pharmaceutical
GB0024318D0 (en) Pharmaceutical compounds
GB0019224D0 (en) Novel pharmaceutical
GB0019226D0 (en) Novel pharmaceutical
GB0021487D0 (en) Pharmaceutical
GB0023971D0 (en) Novel pharmaceutical
GB0014005D0 (en) Novel pharmaceutical
GB0005366D0 (en) Pharmaceutical compounds
GB0012293D0 (en) Pharmaceutical combination
GB0021785D0 (en) Novel Pharmaceutical
HRP20030067A2 (en) Novel pharmaceutical
GB0023970D0 (en) Novel pharmaceutical
EG24200A (en) Novel pharmaceutical
GB0004020D0 (en) Pharmaceutical
GB0017141D0 (en) Pharmaceutical
GB0016563D0 (en) Pharmaceutical
GB0013001D0 (en) Pharmaceutical

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)